Cargando…

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities

SIMPLE SUMMARY: The growing interest in immunotherapy for the treatment of multiple myeloma demands a deep knowledge of the complex interactions between malignant and immune cells within the bone marrow. Indeed, understanding the cellular and molecular mechanisms underlying this network should repre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botta, Cirino, Mendicino, Francesco, Martino, Enrica Antonia, Vigna, Ernesto, Ronchetti, Domenica, Correale, Pierpaolo, Morabito, Fortunato, Neri, Antonino, Gentile, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268448/ https://www.ncbi.nlm.nih.gov/pubmed/34203150 http://dx.doi.org/10.3390/cancers13133213

Ejemplares similares

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report
por: Botta, Cirino, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma
por: Todoerti, Katia, et al.
Publicado: (2021)

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
por: Todoerti, Katia, et al.
Publicado: (2021)

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
por: Todoerti, Katia, et al.
Publicado: (2021)

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma
por: Amodio, Nicola, et al.
Publicado: (2019)

Long Non-Coding RNAs in Multiple Myeloma
por: Nobili, Lucia, et al.
Publicado: (2018)

In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2016)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2018)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
por: Morabito, Fortunato, et al.
Publicado: (2022)

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2016)

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
por: Botta, Cirino, et al.
Publicado: (2022)

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2008)

P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
por: Martino, E. A., et al.
Publicado: (2022)

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
por: Morabito, Fortunato, et al.
Publicado: (2021)

Long non-coding RNAs in B-cell malignancies: a comprehensive overview
por: Nobili, Lucia, et al.
Publicado: (2017)

GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2023)

Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2022)

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
por: Platonova, Natalia, et al.
Publicado: (2023)

Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
por: Mereu, Elisabetta, et al.
Publicado: (2023)

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
por: Ronchetti, Domenica, et al.
Publicado: (2020)

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival
por: Botta, C, et al.
Publicado: (2016)

miR-22 suppresses DNA ligase III addiction in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2018)

P847: BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.
por: Traini, Valentina, et al.
Publicado: (2023)

Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia
por: Ronchetti, Domenica, et al.
Publicado: (2013)

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
por: Larrayoz, Marta, et al.
Publicado: (2023)

Inflammatory status affects the antitumor activity of poly-epitope-peptide vaccination against the thymidylate synthase in metastatic colo-rectal cancer patients enrolled in TSPP/VAC-1 Phase Ib trial
por: Correale, Pierpaolo, et al.
Publicado: (2015)

Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs
por: D’Aquila, Patrizia, et al.
Publicado: (2021)

Complement Evasion in Borrelia spirochetes: Mechanisms and Opportunities for Intervention
por: Locke, Jonathan W.
Publicado: (2019)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
por: Gentile, M, et al.
Publicado: (2010)

The Credibility Question: Challenge or Opportunity?
por: Forner, Kristin
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_grigplbih57jjd5hob5002qvof